Senate BillNo. 139


Introduced by Senator Galgiani

(Principal coauthor: Assembly Member Lackey)

January 26, 2015


An act to amend Sections 11357.5 and 11375.5 of the Health and Safety Code, relating to controlled substances, and declaring the urgency thereof, to take effect immediately.

LEGISLATIVE COUNSEL’S DIGEST

SB 139, as introduced, Galgiani. Controlled substances.

Existing law makes it a misdemeanor to sell, dispense, distribute, furnish, administer, or give, or offer to sell, dispense, distribute, furnish, administer, or give, or possess for sale, any synthetic stimulant compound or any specified synthetic stimulant derivative. Existing law also makes it a misdemeanor to sell, dispense, distribute, furnish, administer, or give, or offer to sell, dispense, distribute, furnish, administer, or give, or possess for sale, any synthetic cannabinoid compound or any synthetic cannabinoid derivative. Existing law, beginning January 1, 2016, makes it an infraction to use or possess those drugs.

This bill would expand the definition of a synthetic stimulant compound and a synthetic cannabinoid for purposes of existing law. The bill would provide that a first offense of using or possessing those substances is punishable as an infraction, a 2nd offense is punishable as an infraction or a misdemeanor, and a 3rd or subsequent offense is punishable as a misdemeanor. By expanding the scope of existing crimes and by increasing the penalty for existing crimes, this bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

This bill would declare that it is to take effect immediately as an urgency statute.

Vote: 23. Appropriation: no. Fiscal committee: yes. State-mandated local program: yes.

The people of the State of California do enact as follows:

P2    1

SECTION 1.  

Section 11357.5 of the Health and Safety Code,
2as added by Section 2 of Chapter 372 of the Statutes of 2014, is
3amended to read:

4

11357.5.  

(a) Every person who sells, dispenses, distributes,
5furnishes, administers, or gives, or offers to sell, dispense,
6distribute, furnish, administer, or give, or possesses for sale any
7synthetic cannabinoid compound, or any synthetic cannabinoid
8derivative, to any person, is guilty of a misdemeanor, punishable
9by imprisonment in a county jail not to exceed six months, or by
10a fine not to exceed one thousand dollars ($1,000), or by both that
11fine and imprisonment.

12(b) Every person who uses or possesses any synthetic
13cannabinoid compound, or any synthetic cannabinoid derivative,
14is guilty ofbegin delete an infraction, punishable by a fine not to exceed two
15hundred fifty dollars ($250).end delete
begin insert a public offense, punishable as
16follows:end insert

begin insert

17(1) A first offense is an infraction punishable by a fine not
18exceeding two hundred fifty dollars ($250).

end insert
begin insert

19(2) A second offense is an infraction punishable by a fine not
20exceeding two hundred fifty dollars ($250) or a misdemeanor
21punishable by imprisonment in a county jail not exceeding six
22months, a fine not exceeding five hundred dollars ($500), or by
23both that fine and imprisonment.

end insert
begin insert

24(3) A third or subsequent offense is a misdemeanor punishable
25by imprisonment in a county jail not exceeding six months, or by
26a fine not exceeding one thousand dollars ($1,000), or by both
27that fine and imprisonment.

end insert

P3    1(c) As used in this section, the term “synthetic cannabinoid
2compound” refers to any of the following substances:

begin delete

3(1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018).

end delete
begin delete

4(2) 1-butyl-3-(1-naphthoyl)indole (JWH-073).

end delete
begin delete

5(3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole
6(JWH-200).

end delete
begin delete

7(4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
8(CP-47,497).

end delete
begin delete

9(5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
10(cannabicyclohexanol; CP-47,497 C8 homologue).

end delete
begin delete

11(d) This section shall become operative on January 1, 2016.

end delete
begin insert

12(1) Adamantoylindoles or adamantoylindazoles, which includes
13adamantyl carboxamide indoles and adamantyl carboxamide
14indazoles, or any compound structurally derived from
153-(1-adamantoyl)indole, 3-(1-adamantoyl)indazole,
163-(2-adamantoyl)indole,
17N-(1-adamantyl)-1H-indole-3-carboxamide, or
18N-(1-adamantyl)-1H-indazole-3-carboxamide by substitution at
19the nitrogen atom of the indole or indazole ring with alkyl,
20haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
21cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
222-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
231-(N-methyl-3-morpholinyl)methyl, or
24(tetrahydropyran-4-yl)methyl group, whether or not further
25substituted in the indole or indazole ring to any extent and whether
26or not substituted in the adamantyl ring to any extent, including,
27but not limited to, 2NE1, 5F-AKB-48, AB-001, AKB-48, AM-1248,
28JWH-018 adamantyl carboxamide, STS-135.

end insert
begin insert

29(2) Benzoylindoles, which includes any compound structurally
30derived from a 3-(benzoyl)indole structure with substitution at the
31nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl,
32hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
331-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
341-(N-methyl-2-pyrrolidinyl)methyl,
351-(N-methyl-3-morpholinyl)methyl, or
36(tetrahydropyran-4-yl)methyl group, whether or not further
37substituted in the indole ring to any extent and whether or not
38substituted in the phenyl ring to any extent, including, but not
39limited to, AM-630, AM-661, AM-679, AM-694, AM-1241,
40AM-2233, RCS-4, WIN 48,098 (Pravadoline).

end insert
begin insert

P4    1(3) Cyclohexylphenols, which includes any compound
2structurally derived from 2-(3-hydroxycyclohexyl)phenol by
3substitution at the 5-position of the phenolic ring by alkyl,
4haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl,
5cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
62-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
71-(N-methyl-3-morpholinyl)methyl, or
8(tetrahydropyran-4-yl)methyl group, whether or not further
9substituted in the cyclohexyl ring to any extent, including, but not
10limited to, CP 47,497, CP 55,490, CP 55,940, CP 56,667,
11cannabicyclohexanol.

end insert
begin insert

12(4) Cyclopropanoylindoles, which includes any compound
13structurally derived from 3-(cyclopropylmethanoyl)indole,
143-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole
15or 3-(cyclopentylmethanone)indole by substitution at the nitrogen
16atom of the indole ring, whether or not further substituted in the
17indole ring to any extent, whether or not substituted on the
18cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent.

end insert
begin insert

19(5) Naphthoylindoles, which includes any compound structurally
20derived from 3-(1-naphthoyl)indole or
211H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen
22atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
23hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
241-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group,
251-(N-methyl-2-pyrrolidinyl)methyl,
261-(N-methyl-3-morpholinyl)methyl, or
27(tetrahydropyran-4-yl)methyl group, whether or not further
28substituted in the naphthyl ring to any extent, including, but not
29limited to, AM-678, AM-1220, AM-1221, AM-1235, AM-2201,
30AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011,
31JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022,
32JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070,
33JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080,
34JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116,
35JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166,
36JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198,
37JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234,
38JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242,
39JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395,
P5    1JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413,
2JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55,212.

end insert
begin insert

3(6) Naphthoylnaphthalenes, which includes any compound
4structurally derived from naphthalene-1-yl-(naphthalene-1-yl)
5methanone with substitutions on either of the naphthalene rings
6to any extent, including, but not limited to, CB-13.

end insert
begin insert

7(7) Naphthoylpyrroles, which includes any compound
8structurally derived from 3-(1-naphthoyl)pyrrole by substitution
9at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl,
10cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl,
11cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
122-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
13 1-(N-methyl-3-morpholinyl)methyl, or
14(tetrahydropyran-4-yl)methyl group, whether or not further
15substituted in the pyrrole ring to any extent and whether or not
16substituted in the naphthyl ring to any extent, including, but not
17limited to, JWH-030, JWH-031, JWH-145, JWH-146, JWH-147,
18JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246,
19JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346,
20JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368,
21JWH-369, JWH-370, JWH-371, JWH-373, JWH-392.

end insert
begin insert

22(8) Naphthylmethylindenes, which includes any compound
23containing a naphthylideneindene structure or which is structurally
24derived from 1-(1-naphthylmethyl)indene with substitution at the
253-position of the indene ring by alkyl, haloalkyl, cyanoalkyl,
26hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
271-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
281-(N-methyl-2-pyrrolidinyl)methyl,
291-(N-methyl-3-morpholinyl)methyl, or
30 (tetrahydropyran-4-yl)methyl group, whether or not further
31substituted in the indene ring to any extent and whether or not
32substituted in the naphthyl ring to any extent, including, but not
33limited to, JWH-171, JWH-176, JWH-220.

end insert
begin insert

34(9) Naphthylmethylindoles, which includes any compound
35structurally derived from an H-indol-3-yl-(1-naphthyl) methane
36by substitution at the nitrogen atom of the indole ring by alkyl,
37haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl,
38cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
392-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
401-(N-methyl-3-morpholinyl)methyl, or
P6    1(tetrahydropyran-4-yl)methyl group, whether or not further
2substituted in the indole ring to any extent and whether or not
3substituted in the naphthyl ring to any extent, including, but not
4limited to, JWH-175, JWH-184, JWH-185, JWH-192, JWH-194,
5JWH-195, JWH-196, JWH-197, JWH-199.

end insert
begin insert

6(10) Phenylacetylindoles, which includes any compound
7structurally derived from 3-phenylacetylindole by substitution at
8the nitrogen atom of the indole ring with alkyl, haloalkyl,
9cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl,
10cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
112-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
121-(N-methyl-3-morpholinyl)methyl, or
13(tetrahydropyran-4-yl)methyl group, whether or not further
14substituted in the indole ring to any extent and whether or not
15substituted in the phenyl ring to any extent, including, but not
16limited to, cannabipiperidiethanone, JWH-167, JWH-201,
17JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207,
18JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250,
19JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305,
20JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315,
21JWH-316, RCS-8.

end insert
begin insert

22(11) Quinolinylindolecarboxylates, which includes any
23compound structurally derived from
24quinolin-8-yl-1H-indole-3-carboxylate by substitution at the
25nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl,
26halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl,
27cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl,
28(4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or
29not further substituted in the indole ring to any extent, whether or
30not substituted in the quinoline ring to any extent, including, but
31not limited to, BB-22, 5-Fluoro-PB-22, PB-22.

end insert
begin insert

32(12) Tetramethylcyclopropanoylindoles, which includes any
33compound structurally derived from
343-tetramethylcyclopropanoylindole,
353-(1-tetramethylcyclopropyl)indole,
363-(2,2,3,3-tetramethylcyclopropyl)indole or
373-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole with substitution
38at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
39cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl,
40cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
P7    12-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
21-(N-methyl-3-morpholinyl)methyl, or
3(tetrahydropyran-4-yl)methyl group whether or not further
4substituted in the indole ring to any extent and whether or not
5substituted in the tetramethylcyclopropanoyl ring to any extent,
6including, but not limited to, 5-bromo-UR-144, 5-chloro-UR-144,
75-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, XLR11.

end insert
begin insert

8(13) Tetramethylcyclopropane-thiazole carboxamides, which
9includes any compound structurally derived from
102,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide
11by substitution at the nitrogen atom of the thiazole ring by alkyl,
12haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy,
13cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl,
14(N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or
152-(4-morpholinyl)alkyl, whether or not further substituted in the
16thiazole ring to any extent, whether or not substituted in the
17tetramethylcyclopropyl ring to any extent, including, but not limited
18to, A-836,339.

end insert
begin insert

19(14) Unclassified synthetic cannabinoids, which includes all of
20the following:

end insert
begin insert

21(A) AM-087, (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)-6,6,9-t
22rimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol.

end insert
begin insert

23(B) AM-356, methanandamide, including (5Z,8Z,11Z,14Z)-N-[
24(1R)-2-hydroxy-1-methylethyl]icosa-5,8,11,14-tetraenamide and
25arachidonyl-1'-hydroxy-2'-propylamide.

end insert
begin insert

26(C) AM-411, (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6
27a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol.

end insert
begin insert

28(D) AM-855, (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1
29,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol.

end insert
begin insert

30(E) AM-905, (6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol.

end insert
begin insert

(F) AM-906, (6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol.

end insert
begin insert

(G) AM-2389, (6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol.

end insert
begin insert

(H) BAY 38-7271, (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate.

end insert
begin insert

(I) CP 50,556-1, Levonantradol, including 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; [(6S,6aR,9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; and [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate.

end insert
begin insert

(J) HU-210, including (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol and 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol.

end insert
begin insert

(K) HU-211, Dexanabinol, including (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol and (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl- 3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol.

end insert
begin insert

(L) HU-243, 3-dimethylheptyl-11-hydroxyhexahydrocannabinol.

end insert
begin insert

(M) HU-308, [(91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol.

end insert
begin insert

(N) HU-331, 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione.

end insert
begin insert

(O) HU-336, (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione.

end insert
begin insert

(P) JTE-907, N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide.

end insert
begin insert

(Q) JWH-051, ((6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol.

end insert
begin insert

(R) JWH-057 (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran.

end insert
begin insert

(S) JWH-133 (6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H-dibenzo[b,d]pyran.

end insert
begin insert

(T) JWH-359, (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene.

end insert
begin insert

(U) URB-597 [3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate.

end insert
begin insert

(V) URB-602 [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; OR cyclohexyl [1,1'-biphenyl]-3-ylcarbamate.

end insert
begin insert

(W) URB-754 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one.

end insert
begin insert

(X) URB-937 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate.

end insert
begin insert

(Y) WIN 55,212-2, including (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone and [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone.

end insert
P9   10

SEC. 2.  

Section 11375.5 of the Health and Safety Code, as
11added by Section 4 of Chapter 372 of the Statutes of 2014, is
12amended to read:

13

11375.5.  

(a) Every person who sells, dispenses, distributes,
14furnishes, administers, or gives, or offers to sell, dispense,
15distribute, furnish, administer, or give, any synthetic stimulant
16compound specified in subdivision (c), or any synthetic stimulant
17derivative, to any person, or who possesses that compound or
18derivative for sale, is guilty of a misdemeanor, punishable by
19imprisonment in a county jail not to exceed six months, or by a
20fine not to exceed one thousand dollars ($1,000), or by both that
21fine and imprisonment.

22(b) Every person who uses or possesses any synthetic stimulant
23compound specified in subdivision (c), or any synthetic stimulant
24derivative, is guilty ofbegin delete an infraction, punishable by a fine not to
25exceed two hundred fifty dollars ($250).end delete
begin insert a public offense
26punishable as follows:end insert

begin insert

27(1) A first offense is an infraction punishable by a fine not
28exceeding two hundred fifty dollars ($250).

end insert
begin insert

29(2) A second offense is an infraction punishable by a fine not
30exceeding two hundred fifty dollars ($250) or a misdemeanor
31punishable by imprisonment in a county jail not exceeding six
32months, a fine not exceeding five hundred dollars ($500), or by
33both that fine and imprisonment.

end insert
begin insert

34(3) A third or subsequent offense is a misdemeanor punishable
35by imprisonment in a county jail not exceeding six months, or by
36a fine not exceeding one thousand dollars ($1,000), or by both
37that fine and imprisonment.

end insert

38(c) Unless specifically excepted, or contained within a
39pharmaceutical product approved by the United States Food and
40Drug Administration, or unless listed in another schedule,
P10   1subdivisions (a) and (b) apply to any material, compound, mixture,
2or preparation which contains any quantity ofbegin delete the following
3substances having a stimulant effect on the central nervous system,end delete

4begin insert a substance,end insert including its salts, isomers, esters, or ethers, and salts
5of isomers, esters, or ethers whenever the existence of such salts,
6isomers, esters, or ethers, and salts of isomers, esters, or ethers is
7begin delete possible within any of the following specific chemical designations:end delete
8begin insert possible, that is structurally derived from
92-amino-1-phenyl-1-propanone by modification in one of the
10following ways:end insert

begin delete

11(1) Naphthylpyrovalerone whether or not further substituted in
12the naphthyl ring to any extent with alkyl, alkoxy, alkylenedioxy,
13haloalkyl, or halide substituents, whether or not further substituted
14in the naphthyl ring by one or more other univalent substituents,
15or whether or not further substituted in the carbon chain at the 3-,
164-, or 5-position with an alkyl substituent.

17(2) 2-amino-1-phenyl-1-propanone (cathinone) or variation in
18any of the following ways:

19(A) By substitution in the phenyl ring to any extent with alkyl,
20alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether
21or not further substituted in the phenyl ring by one or more other
22univalent substituents.

23(B) By substitution at the 3-position with an alkyl substituent.

24(C) By substitution at the nitrogen atom with alkyl, dialkyl, or
25benzyl groups, or by inclusion of the nitrogen atom in a cyclic
26structure.

end delete
begin insert

27(1) By substitution in the phenyl ring to any extent with alkyl,
28alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether
29or not further substituted in the phenyl ring by one or more other
30univalent substituents.

end insert
begin insert

31(2) By substitution at the 3-position with an alkyl substituent.

end insert
begin insert

32(3) By substitution at the nitrogen atom with alkyl or dialkyl
33groups, or by inclusion of the nitrogen atom in a cyclic structure.

end insert

34(d) This section shall not prohibit prosecution under any other
35provision of law.

begin delete

36(e) This section shall become operative on January 1, 2016.

end delete
37

SEC. 3.  

No reimbursement is required by this act pursuant to
38Section 6 of Article XIII B of the California Constitution because
39the only costs that may be incurred by a local agency or school
40district will be incurred because this act creates a new crime or
P11   1infraction, eliminates a crime or infraction, or changes the penalty
2for a crime or infraction, within the meaning of Section 17556 of
3the Government Code, or changes the definition of a crime within
4the meaning of Section 6 of Article XIII B of the California
5Constitution.

6

SEC. 4.  

This act is an urgency statute necessary for the
7immediate preservation of the public peace, health, or safety within
8the meaning of Article IV of the Constitution and shall go into
9immediate effect. The facts constituting the necessity are:

10In order to prevent any harm that may be caused by the controlled
11substances described in this act at the earliest possible time, it is
12necessary that this act take effect immediately.


CORRECTIONS:

Text--Pages 3, 4, 7 and 8.




O

Corrected 2-9-15—See last page.     99